
News|Articles|June 20, 2024
Emerging Biosimilars and the Importance of Identifying Experienced Providers
Author(s)PurpleLab
Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Trending on Applied Clinical Trials Online
1
Securing Comparator Drugs in Competitive EU Markets: Challenges and Practical Solutions
2
Verana Health Merges With COTA to Expand Real-World Data Capabilities Across Oncology and Specialty Care
3
BostonGene Expands AI-Driven Oncology Collaborations with New AstraZeneca Deal
4
Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial
5